drugset / Trial / NCT06667206
Earlier Prime-BOOST Schedule to Improve MEasles Protection in High Burden Settings
Phase 2
Unknown
450 enrolled
University of Oxford
MU-JHU CARE · collabSt George's, University of London · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This is a phase IIb clinical trial investigating the non-inferiority of immune responses in children given two doses of measles vaccine at different timepoints. The study will randomise 450 children to 3 groups: group A will receive measles containing vaccine (MCV) at 6 and 12 months ; group B at 9 and 18 months; Group C at 6 and 18 months.
Timeline
- Start
- 2023-11-15
- Primary completion
- 2026-05-10
- Completion
- 2026-05-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Licenced Measles-Rubella vaccine | Vaccine | — | — |